Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant
Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant
Not yet recruiting · NCT05982275 · Registry updated 2024-05-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Not yet recruiting | Phase 1 / Phase 2 | 2024-05-14 | NCT05982275 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 22 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Complejo Asistencial Universitario de Salamanca | Salamanca | Spain | 13 |
| Hospital Clínico de Valencia | Valencia | Spain | 5 |
| Hospital Santa Creu i Sant Pau | Barcelona | Spain | 1 |
| Hospital Universitario Marques de Valdecilla | Santander | Spain | 38 |
| José Antonio Pérez Simón | Seville | Spain | 1 |